Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Moderate Buy" by Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $17.75.

A number of research firms have issued reports on ATRA. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They issued a "buy" rating and a $25.00 target price for the company. TD Cowen upgraded Atara Biotherapeutics to a "strong-buy" rating in a research note on Friday, November 29th. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 21st. HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group dropped their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a "buy" rating on the stock in a research note on Friday, January 17th.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics during the second quarter worth about $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics during the second quarter worth about $53,000. FMR LLC increased its position in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. Vestal Point Capital LP raised its stake in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company's stock valued at $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Finally, State Street Corp raised its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company's stock.

Atara Biotherapeutics Stock Up 9.2 %

NASDAQ ATRA traded up $0.78 during trading hours on Friday, reaching $9.30. 180,402 shares of the company were exchanged, compared to its average volume of 425,721. The stock has a market capitalization of $53.57 million, a P/E ratio of -0.36 and a beta of 0.46. Atara Biotherapeutics has a 1 year low of $5.40 and a 1 year high of $31.75. The business's 50 day simple moving average is $11.56 and its 200-day simple moving average is $9.84.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analysts' expectations of $23.00 million. During the same quarter in the previous year, the business earned ($16.50) EPS. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.